Pharmacotherapy for the management of overweight and obesity

被引：0
作者：
Forner, Patrice [1 ,2 ]
Hocking, Samantha [1 ,3 ,4 ]
机构：
[1] Royal Prince Alfred Hosp, Dept Endocrinol & Metab, Sydney, NSW, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[4] Univ Sydney, Charles Perkins Ctr, Diabet NSW & ACT, Sydney, NSW, Australia
来源：
AUSTRALIAN JOURNAL OF GENERAL PRACTICE | 2025年 / 54卷 / 04期
关键词：
CONTROLLED-RELEASE; CONTROLLED-TRIAL; WEIGHT-LOSS; COMBINATION; TOPIRAMATE; THERAPY;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Background Lifestyle intervention is the mainstay of obesity management; however, behavioural modification alone produces only modest results and attempts to create a negative energy balance are offset by a biological response to maintain weight. Pharmacotherapy is indicated as an adjunct for those living with obesity (body mass index [BMI] >= 30 kg/m(2)) or those who are overweight (BMI >= 27 kg/m(2)) with a least one weight-related complication. Objective This article provides an update on pharmacotherapy for the management of overweight and obesity. Discussion Pharmacotherapy is a useful adjunct for the treatment of obesity and obesity-related comorbidities. When considering pharmacotherapy, thought must be given to efficacy, contraindications, potential side effects, cost and duration of treatment.
引用
收藏
页码：196 / 201
页数：6
相关论文
共 36 条
[1]   Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials [J].
Abd El Aziz, Mirna ;
Cahyadi, Oscar ;
Meier, Juris J. ;
Schmidt, Wolfgang E. ;
Nauck, Michael A. .
DIABETES OBESITY & METABOLISM, 2020, 22 (04) :699-704
[2]  
[Anonymous], 2024, AUSTR I HLTH WELFARE
[3]  
Australian and New Zealand Clinical Trials Registry, 2024, Australian Clinical Trials
[4]  
Australian Medicines Handbook (AMH), 2025, Endocrine drugs
[5]   The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, SR ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) :443-469
[6]   Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis [J].
Bliddal, Henning ;
Bays, Harold ;
Czernichow, Sebastien ;
Hemmingsson, Joanna Udden ;
Hjelmesaeth, Joran ;
Morville, Thomas Hoffmann ;
Koroleva, Anna ;
Neergaard, Jesper Skov ;
Sanchez, Patricia Velez ;
Wharton, Sean ;
Wizert, Alicja ;
Kristensen, Lars E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (17) :1573-1583
[7]   The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease [J].
Du, Haiyang ;
Meng, Xiaoyu ;
Yao, Yu ;
Xu, Jun .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[8]   One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor [J].
Finer, N ;
James, WPT ;
Kopelman, PG ;
Lean, MEJ ;
Williams, G .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) :306-313
[9]   Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [J].
Gadde, Kishore M. ;
Allison, David B. ;
Ryan, Donna H. ;
Peterson, Craig A. ;
Troupin, Barbara ;
Schwiers, Michael L. ;
Day, Wesley W. .
LANCET, 2011, 377 (9774) :1341-1352
[10]   Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects [J].
Goldsmith, Rochelle ;
Joanisse, Denis R. ;
Gallagher, Dympna ;
Pavlovich, Katherine ;
Shamoon, Elisabeth ;
Leibel, Rudolph L. ;
Rosenbaum, Michael .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2010, 298 (01) :R79-R88
1234